Page 6 - Genmark Diagnostics News Today

Syndromic Multiplex Diagnostic Market Analysis, Trends, Top Manufacturers, Share, Growth, Statistics, Opportunities & Forecast to 2028 | Abbott Laboratories, Akonni Biosystems, Inc., Applied BioCode, Inc, BioFire Diagnostics iCrowd Newswire Worldwide Syndromic Multiplex Diagnostic Market Analysis to 2027 is a specialized and in-depth study of the Syndromic Multiplex Diagnostic Market Industry with a focus on the global market trend. The report aims to provide an overview of global Syndromic ...

Coronavirus Testing Kits Market to See Huge Growth by 2026 | Altona Diagnostics, BioMednomics, CTK Biotech iCrowd Newswire Latest released the research study on Global Coronavirus Testing Kits Market, offers a detailed overview of the factors influencing the global business scope. Coronavirus Testing Kits Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the...

Navigating the Choppy Waters of Implementing Rapid Molecular Blood Culture Identification Tests, Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, the featured speakers will discuss how an Infectious Disease Specialist (IDS) can assist with the integration of rapid molecular blood culture identification into a laboratory’s current blood culture workflow. Discover how an IDS is well-positioned to assist in optimizing the use of rapid molecular blood culture identification ...

COVID-19 Detection Test Kits And Consumables Global Market Report 2021: COVID-19 Implications And Growth To 2030 The Business Research Company’s COVID-19 Detection Test Kits and Consumables Global Market Report 2021: COVID-19 Implications And Growth To 2030 LONDON, GREATER LONDON, UK, May 12, 2021 /EINPresswire.com/ -- The escalating demand for cost-effective and quick COVID-19 detection kits coupled with the easing of regulatory processes for COVID-19 detection kits contributed to the growth...

AbbVie announced Q1 results on April 30 that chairman and chief executive officer, Richard A. Gonzalez, described as “ahead of our expectations.” Blockbuster drug, Humira, led the way with global net revenues of $4.867 billion. The company recently took a hit as the suddenly cautious FDA extended its review of JAK inhibitor, Rinvoq (upadacitinib) for atopic dermatitis, requesting an updated assessment of its benefit-risk profile. This follows the news of a delay in the approval of Rinvoq f...

Share: Basel, 22 April 2021 - Roche ((SIX: RO, ROG, OTCQX:RHHBY) and GenMark Diagnostics, Inc. today announced that Roches wholly owned subsidiary Geronimo Acquisition Corp. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) at a price of USD 24.05 per share in cash. The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on 21 Ap...

ADVERTISEMENT ADVERTISEMENT GenMark Investor Wants Records On $1.8B Roche Deal Law360 (April 21, 2021, 10:31 PM EDT) -- A GenMark Diagnostics shareholder sued the biotech company Wednesday in Delaware Chancery Court in a bid to gain access to records regarding Roches planned $1.8 billion acquisition of the disease-testing business, saying there are reasons to suspect the deal was "the result of a potentially conflicted process." The Switzerland-based F. Hoffmann-La Roche Ltd. announced in March...

Commenting on the Group’s performance in the first quarter, Roche CEO Severin Schwan said: “In 2021, Roche remains strongly committed to the fight against COVID-19. The uptake of our recently introduced diagnostic tests and medicines remains strong, while we continue to see the expected impact from biosimilars on sales of our established medicines. Our broad product pipeline keeps making good progress. I am particularly pleased about the highly encouraging study results of our immunotherapy...

Group sales increase 3% 1 at constant exchange rates (CER); 1% decline in Swiss francs, as a result of the appreciation of the Swiss franc Pharmaceuticals Division sales: As expected, significant impact from biosimilars (CHF -1.6 billion) Base effect from the strong first quarter 2020 (negative impact of the pandemic only since April 2020) Overall, this results in a 9% decline in sales. Diagnostics Division sales: Roches contributions to the fight again...

Roche Stock Up On Higher Q1 Sales At Constant Rates; Backs FY21 Outlook SOUTH SAN FRANCISCO (dpa-AFX) - Shares of Roche were gaining around 2 percent in Swiss trading after the drug major reported Wednesday a 3 percent rise in first-quarter sales at constant currency basis mainly driven by strong growth in Diagnostics Division. Sales, on a reported basis, edged down 1 percent mainly with significant impact from biosimilars. Looking ahead for fiscal 2021, the company continues to expect sales to...